Blog

Benjamin Ebert: Privileged to end this year a few months into my tenure as President and CEO of Dana-Farber Cancer Institute

Benjamin Ebert/dkfz.de

Dec 28, 2024, 18:19

Benjamin Ebert: Privileged to end this year a few months into my tenure as President and CEO of Dana-Farber Cancer Institute

Benjamin Ebert, President and CEO of Dana-Farber Cancer Institute, shared a post on LinkedIn:

“With the holidays upon us and as 2024 nears its end, I am reflecting on what an incredible year it has been. I have the privilege to end this year a few months into my tenure as President and CEO of Dana-Farber Cancer Institute.

I trained here and have worked at the Institute a long time. I know it well. Yet, in my new role, I’m truly seeing the breadth of our expertise, in every corner, in every role. This is such a special organization, made so by our remarkable workforce. It is an honor to work alongside such skilled and devoted colleagues.

As we reflect on our tremendous work in 2024 and the progress we’ve made against cancer in its many forms, I look forward to beginning another promising year for Dana-Farber. Together we will continue to blend exceptional, patient-centric cancer care with innovative cancer research, and do all we can to help patients of all ages from all communities.”

More posts featuring Benjamin Ebert.

Read the post “The New President and CEO of Dana-Farber Cancer Center – Benjamin Ebert” on oncodaily.com.

Benjamin L. Ebert is the President and CEO of Dana-Farber Cancer Institute. He is also George P. Canellos Professor of Medicine at Harvard Medical School, a Howard Hughes Medical Institute Investigator and an Institute Member of the Broad Institute.

Ebert, a member of the National Academy of Medicine, American Society for Clinical Investigation, and the Association of American Physicians, focuses on the molecular basis and treatment of hematologic malignancies, especially myelodysplastic syndromes (MDS).